Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
94.26-0.63 (-0.66%)
At close: 05:39PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close94.89
Open94.31
Bid0.00 x 0
Ask0.00 x 0
Day's Range93.07 - 95.16
52 Week Range74.92 - 95.16
Volume3,003,341
Avg. Volume1,963,493
Market Cap118.324B
Beta (5Y Monthly)0.46
PE Ratio (TTM)19.23
EPS (TTM)4.90
Earnings DateFeb 03, 2022 - Feb 07, 2022
Forward Dividend & Yield3.20 (3.63%)
Ex-Dividend DateMay 05, 2021
1y Target Est103.64
  • Barrons.com

    Moderna Faces Challenges Beyond the Covid Vaccine. Its Stock Is Still a Buy.

    The biotech faces stiffer competition and growing pains as it makes a transition to a postpandemic vaccine market. Its big pile of cash should help.

  • Benzinga

    Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

    Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have voluntarily withdrawn their application with the FDA for the expanded use of Libtayo in patients with advanced cervical cancer. The application for the monoclonal antibody as the second-line of treatment in the patients was withdrawn "after the companies and the FDA were not able to align on certain post-marketing studies." The FDA had accepted the supplemental application for priority review in September,

  • Reuters

    UPDATE 1-Regeneron, Sanofi withdraw FDA application for cancer drug's expanded use

    Regeneron Pharmaceuticals Inc and its partner Sanofi voluntarily withdrew their application with the U.S. drug regulator for the expanded use of their anti-cancer drug Libtayo in patients with advanced cervical cancer. The application for the monoclonal antibody as the second-line of treatment in the patients was withdrawn "after the companies and the U.S. Food and Drug Administration were not able to align on certain post-marketing studies", the companies said on Friday. The FDA had accepted the supplemental application for priority review in September.

Advertisement
Advertisement